Illumina Inc (ILMN) News - XNAS | Morningstar

Skip to Content

News

Illumina Supports Israel's National Program to Accelerate Diagnoses of Critically-Ill Newborns with Suspected Genetic Disease

Provided by PR Newswire Oct 27, 2021 7:05 AM UTC

Illumina to Host Inaugural ESG Investor Event on Tuesday, November 16, 2021

Provided by PR Newswire Oct 20, 2021 10:00 PM UTC

Illumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL

Provided by PR Newswire Oct 14, 2021 11:35 PM UTC

Illumina to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021

Provided by PR Newswire Oct 13, 2021 9:00 PM UTC

Illumina Expands Presence in Latin America

Provided by PR Newswire Sep 30, 2021 1:15 PM UTC

Randomized trial demonstrates whole-genome sequencing leads to precision care for critically ill infants

Provided by PR Newswire Sep 27, 2021 3:08 PM UTC

Dante Labs Announces Appointment of Global Legal Expert Rachel Haverfield as General Counsel to its Expanding Leadership Team

Provided by GlobeNewswire Sep 16, 2021 11:30 AM UTC

Illumina Accelerator Invests in Seven Genomics Startups for Third Global Cycle

Provided by PR Newswire Sep 15, 2021 1:15 PM UTC

Dante Labs Announces Expansion of its Finance Team with the Appointment of Andre Nel as Chief Financial Officer, Dalila Rahmani as Chief Accounting Officer, Laura D’Angelo as VP Investor Relations and Omar Elbakshish as Senior Director

Provided by GlobeNewswire Sep 14, 2021 11:30 AM UTC

Global News Select

UK NHS to Launch First Trial of Grail's Cancer-Detection Test

Provided by Dow Jones Sep 13, 2021 1:31 PM UTC

Transparency is our policy. Learn how it impacts everything we do.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.